* Scale and presence underpin growth and margin expansion * Sharper execution on cross-segment syner...
* Top-line pressure persisting, better cost control * We cut '25e-'27e adj.
Nettoomsättningen för det andra kvartalet 2025 uppgick till 142,1 MSEK (114,2), motsvarande en organ...
Redeye gives an initial comment on the positive news that BioArctic has signed an “option, collabora...
Redeye comments on Lipigon’s Q2 report. At the end of June, the company recruited the last patient t...
Redeye provides a research update following the Q2 report published by Isofol earlier today.
Redeye provides an initial take following the release of Corline’s Q2 2025 report.
* Q2 adj. EBITDA 25% below consensus on 12% sales miss * FY guidance cut; cons '25e EBITDA to come d...
* Q2 EBIT SEK -74m (vs. ABGSCe 103m) * EBIT negatively impacted by delay in Pome project timeline * ...
Solwers reported its results for Q2 with sales of EUR 21.
Acuvi redovisade ökad nettoomsättning och EBIT i det andra kvartalet.
Redeye provides an update following Neola Medical’s Q2 2025 report.
We hosted NoHo Partners' CEO Jarno Suominen for a lunch meeting today in Helsinki.
Redeye comments on Elicera reporting data from cohort 2 in the ongoing CARMA study.
Nettoomsättningen för det andra kvartalet uppgick till 6,6 MEURO (10,2), vilket motsvarade en minskn...
Redeye comments on Active Biotech's second quarter report.
Redeye views InfraCom’s Q2 2025 results as mixed, with a declining top line contrasted by rising EBI...
Egetis has rapidly transferred all but one German patient, supporting the launch and indicating posi...
Cantargia’s Q2 report covers one of the most eventful periods in the company’s history.
Redeye has updated its estimates and valuation for Sleep Cycle following the Q2 2025 report, which w...
